Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × nintedanib × Tumor-Agnostic × Clear all

Phase

Status

Completed 5 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 4 Cisplatin 4 Gemcitabine 3 trametinib 2 repotrectinib 2 pembrolizumab 2 enzalutamide 2 atezolizumab 2 Surveys and Questionnaires 2 SS1(dsFv)PE38 2 Radiotherapy 2 Radiosurgery 2 Paclitaxel 2 Nivolumab 2 veliparib 1 vadimezan 1 toripalimab 1 talazoparib 1 sintilimab 1 reolysin 1 pertuzumab 1 peginterferon alfa-2a 1 palbociclib 1 onartuzumab 1 nintedanib 1 nimotuzumab 1 naquotinib 1 montanide ISA 51 1 lenvatinib 1 folfirinox 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856867 2017-05-09

MEGAN

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡